EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N ‐Pyrrolidino Fluetonitazene

Severin Zemp, Gaia Alluisetti iD, Wolfgang Weinmann iD, Bettina Schrag, Frank Sporkert iD, Maurine Leclerc iD, Katharina Elisabeth Grafinger iD

Drug Testing and Analysis · 2026-08 · 18 (8) · 1097-1113

DOI: 10.1002/dta.70095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 02.06.2026. Verfasst von Severin Zemp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Forensic Toxicology and Chemistry, Institute of Forensic Medicine Bern, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Pyrrolidines, Analgesics, Opioid. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N ‐pyrrolidino fluetonitazene ( N ‐pyrrolidino‐4′‐(2‐fluoroethoxy) nitazene) also known as fluetonitazepyne, is the fluorinated analogue of etonitazepyne, belonging to the group of new synthetic opioids (NSOs), which are among the fastest‐growing classes of new psychoactive substances. In the present study, the N ‐pyrrolidino fluetonitazene metabolism was investigated in vitro using pooled human liver microJsomes (pHLM) and in authentic samples from a forensic postmortem case. Qualitative analysis was performed using liquid chromatography–high‐resolution tandem mass spectrometry (LC‐HR‐MS/MS). Confirmation and semiquantitative analysis of N ‐pyrrolidino fluetonitazene in urine and blood were carried out using liquid chromatography tandem mass spectrometry (LC–MS/MS). The μ‐opioid (MOR) receptor affinity of N ‐pyrrolidino fluetonitazene was determined using an LC–MS/MS‐based competitive binding assay. In total, eight different metabolites for N ‐pyrrolidino fluetonitazene were tentatively identified in vitro in pHLM incubations of which three ( M2 O ‐dealkylation, M6 oxidative deamination and M8 carboxylation to N ‐butanoic acid) were also found in the postmortem urine sample. In the blood samples, only one metabolite was found ( M9 formed by N ‐acetylation of 5‐aminofluetodesnitazene). This metabolite was only observed in the in vivo samples and was the most abundant metabolite in blood and urine samples. We also detected metabolite M2 (formed by 4′‐hydroxylation), which is common in the metabolism of other nitazepyne‐type substances. For the confirmation of N ‐pyrrolidino fluetonitazene, we recommend including M8 and M9 as analytical target compounds, since they are specific N ‐pyrrolidino fluetonitazene metabolites. Furthermore, we demonstrated that the LC–MS/MS‐based MOR receptor affinity assay yields valid results for N ‐pyrrolidino fluetonitazene that are consistent with those obtained using established radioligand‐based methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, muPyrrolidinesAnalgesics, OpioidHumansTandem Mass SpectrometryMicrosomes, LiverLiquid Chromatography-Mass SpectrometrySubstance Abuse DetectionChromatography, LiquidMaleBenzimidazoles

Substanzen

Receptors, Opioid, muPyrrolidinesAnalgesics, OpioidnitazeneBenzimidazoles

Autor:innen und Institutionen

  • Forensic Toxicology and Chemistry, Institute of Forensic Medicine Bern, University of Bern, Bern, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Department of Forensic Medicine, ICH Central Institute, Sion, Switzerland.
  • Forensic Toxicology and Chemistry Unit, University Centre of Legal Medicine Lausanne-Geneva, Lausanne, Switzerland.

ORCID-Profile: Gaia Alluisetti, Wolfgang Weinmann, Frank Sporkert, Maurine Leclerc, Katharina Elisabeth Grafinger

Förderung

  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Zemp, S., Alluisetti, G., Weinmann, W., Schrag, B., Sporkert, F., Leclerc, M., & Grafinger, K. E. (2026). Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N ‐Pyrrolidino Fluetonitazene. Drug Testing and Analysis, 18(8), 1097-1113. https://doi.org/10.1002/dta.70095

Vancouver

Zemp S, Alluisetti G, Weinmann W, Schrag B, Sporkert F, Leclerc M, et al. Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N ‐Pyrrolidino Fluetonitazene. Drug Testing and Analysis. 2026;18(8):1097-1113. doi:10.1002/dta.70095

BibTeX
@article{Zemp2026,
  author = {Zemp, Severin and Alluisetti, Gaia and Weinmann, Wolfgang and Schrag, Bettina and Sporkert, Frank and Leclerc, Maurine and Grafinger, Katharina Elisabeth},
  title = {Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N ‐Pyrrolidino Fluetonitazene},
  journal = {Drug Testing and Analysis},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1097--1113},
  doi = {10.1002/dta.70095}
}
Kostenlos starten →